Post hoc analysis of VOYAGE/EXCURSION in children 6-11 with type 2 asthma: dupilumab reduced exacerbations v placebo, with effects maintained up to 2 years, whether or not blood eosinophils rose early (22.4% of 156); no safety differences.
Secondary analysisn = 156
Dell et al. Dupilumab outcomes in pediatric asthma by early eosinophil status: Post hoc analysis of VOYAGE/EXCURSION